3 天
GlobalData on MSNBiogen and Stoke Therapeutics to commercialise Dravet syndrome treatmentBiogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...
Market OverviewThe Global RNA Therapeutics Market is valued at USD 13.3 Billion in 2023 and is projected to reach a value ...
Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $24 ...
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company’s product pipeline comprises ATL1102, an antisense inhibitor ...
This is the third drug AZ has licensed in as part of strategic collaboration with the antisense therapeutics specialist , which originally began in 2012 in oncology and was later expanded to cover ...
An investigational antisense oligonucleotide ... 70% of external clinical development costs for the therapy. Stoke Therapeutics CEO Edward Kaye stated: “With Biogen’s deep experience in ...
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently ...
An FIR was registered against ANP district president Abdul Qadir Basikhel, Kunder Hassanzai tehsil chairman Mian Nazeer and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果